Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
$2.67
-1.5%
$3.58
$0.91
$9.40
$49.28MN/A14.95 million shs356,669 shs
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.33
-14.8%
$0.33
$0.25
$1.20
$17.03M1.19171,006 shs4.12 million shs
OpGen, Inc. stock logo
OPGN
OpGen
$4.88
$4.73
$0.53
$5.25
$49.13M-1.689,626 shs38 shs
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
$1.88
+2.2%
$2.35
$1.37
$9.13
$70.83M0.71153,408 shs264,870 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
0.00%-43.19%+34.17%+266,999,900.00%+266,999,900.00%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00%0.00%0.00%-32.71%-69.91%
OpGen, Inc. stock logo
OPGN
OpGen
0.00%-1.61%-0.20%+82.77%+92.89%
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
0.00%+5.62%-11.32%-50.40%-74.14%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/AN/AN/AN/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/AN/AN/AN/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/AN/AN/AN/A
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
0.3114 of 5 stars
0.02.00.00.01.12.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
0.00
N/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00
N/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
0.00
N/AN/AN/A
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/AN/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$29.09M0.59N/AN/A$1.09 per share0.30
OpGen, Inc. stock logo
OPGN
OpGen
$2.67M18.38N/AN/A($11.55) per share-0.42
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
$115K615.87N/AN/A$1.40 per share1.34
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/AN/A0.00N/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
-$26.08MN/A0.00N/A-75.34%-7.96%-5.49%N/A
OpGen, Inc. stock logo
OPGN
OpGen
-$32.67MN/A0.00N/A-1,140.36%N/A-287.58%7/7/2025 (Estimated)
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
-$32.90M-$0.94N/AN/AN/A-28,685.22%-51.35%-37.21%8/6/2025 (Estimated)

Latest ENZ, SERA, BMGL, and OPGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
-$0.24-$0.20+$0.04-$0.20$0.06 million$0.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.40123.08%N/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/A
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A
2.55
2.28
OpGen, Inc. stock logo
OPGN
OpGen
N/A
5.45
5.45
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
N/A
2.02
2.02

Institutional Ownership

CompanyInstitutional Ownership
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
36.90%
OpGen, Inc. stock logo
OPGN
OpGen
2.68%
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
54.64%

Insider Ownership

CompanyInsider Ownership
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
11.40%
OpGen, Inc. stock logo
OPGN
OpGen
43.80%
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
13.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
3618.45 millionN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
52052.40 million46.29 millionOptionable
OpGen, Inc. stock logo
OPGN
OpGen
10010.07 million4.70 millionNot Optionable
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
12037.67 million32.59 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Basel Medical Group stock logo

Basel Medical Group NASDAQ:BMGL

$2.67 -0.04 (-1.48%)
As of 06/18/2025 04:00 PM Eastern

Basel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.

Enzo Biochem stock logo

Enzo Biochem NYSE:ENZ

$0.32 -0.06 (-14.83%)
Closing price 04/17/2025
Extended Trading
$0.32 0.00 (0.00%)
As of 04/17/2025 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

OpGen stock logo

OpGen NASDAQ:OPGN

$4.88 0.00 (0.00%)
As of 06/18/2025

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

Sera Prognostics stock logo

Sera Prognostics NASDAQ:SERA

$1.88 +0.04 (+2.17%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$1.88 0.00 (0.00%)
As of 06/18/2025 06:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.